Showing results (11-20 of 39) with videos related to
Sort By:
Pageof 4
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|June 19, 2022
Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolidHiroshige Mikamo, Makoto Nagashima, Shinya Kusachi, et al.Expert Opinion on Drug Safety|March 13, 2018
Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infectionsCathy Hardalo, Thomas P Lodise, Monique Bidell, et al.The Lancet. Infectious Diseases|June 10, 2014
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trialGregory J Moran, Edward Fang, G Ralph Corey, et al.Antimicrobial Agents and Chemotherapy|November 26, 2014
Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infectionsAndrew F Shorr, Thomas P Lodise, G Ralph Corey, et al.Patient Related Outcome Measures|January 22, 2025
Evaluation of the Content Validity of the COVID-19 Symptoms Daily DiaryJennifer Dine, Yanfen Guan, Mirline Milien, et al.BMC Infectious Diseases|February 28, 2021
A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19Laura Puzniak, Lyn Finelli, Kalvin C Yu, et al.Open Forum Infectious Diseases|June 18, 2021
Effect of Inadequate Empiric Antibacterial Therapy on Hospital Outcomes in SARS-CoV-2-Positive and -Negative US Patients With a Positive Bacterial Culture: A Multicenter Evaluation From March to November 2020Laura Puzniak, Karri A Bauer, Kalvin C Yu, et al.Clinical Pharmacology and Therapeutics|April 5, 2023
Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical OutcomesAkshita Chawla, Ruthie Birger, Hong Wan, et al.Journal of Clinical Pharmacology|September 1, 2022
Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent HemodialysisHwa-Ping Feng, Yogesh T Patel, Zufei Zhang, et al.International Journal of Antimicrobial Agents|January 12, 2021
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)Matthew G Johnson, Christopher Bruno, Mariana Castanheira, et al.Pageof 4